EU Reveals Plan To Speed Development Of New COVID-19 Therapies
Project Includes A ‘Therapeutics Booster’ And R&D/Manufacturing Support
Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.
You may also be interested in...
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
The European Commission has set up a new expert group on virus variants whose tasks will include selecting the criteria for identifying possible new treatments and vaccines for COVID-19.
Rolling reviews are now in progress at the European Medicines Agency for four COVID-19 vaccines and for four potential COVID-19 treatments.